 | | New targets in lipid management |
|  | | Novel Approaches to Modify Lipids and Lipoproteins |
|
 | | Statin Prescription in the UK |
|  | | Percentage of the UK-population with TC > 5 mmol/l |
|
 | | All-Cause Mortality in the UK in those < 75 Years |
|  | | New Approaches to LDL Reduction |
|
 | | Mipomersen: Apo B-100 as a Target |
|  | | Overview of Mipomersen |
|
 | | Antisense |
|  | | Heterozygous Familial Hypercholesterolemia |
|
 | | Mipomersen Significantly Reduced LDL-C |
|  | | Distribution of LDL-C % Change From Baseline |
|
 | | The Rationale |
|  | | Selective Thyroid Receptor Agonist Provides New Treatment Opportunities |
|
 | | Eprotirome is… |
|  | | Eprotirome Monotherapy Efficiently Lowers LDL-C |
|
 | | LDL-C Mean % Change from Baseline |
|  | | PCSK9 Rapid Pace of Research |
|
 | | New Approaches for Raising HDL |
|  | | CETP Levels and CAD risk |
|
 | | Anacetrapib Dose Ranging Study |
|  | | Future |
|
 | | Niacin Flushing Pathway |
|  | | An Overview of the Niacin-Induced Flushing Pathway |
|
 | | Factorial Study: Lipid Efficacy |
|  | | HPS2-THRIVE |
|
 | | ApoA1 Based Therapies |
|  | | Cerenis HDL (CER-001)Homogeneous Drug Product |
|
 | | CER-001 Mobilizes Cholesterol in Rabbits |
|  | | CHI SQUARE Study Design |
|
 | | CHI-SQUARE Study Design |
|  | | IVUS clinical trial using selective delipidated HDL |
|
 | | IVUS Clinical Trial Using Selective Delipidated HDL |
|  | | Results of the IVUS Clinical Trial Using Selective Delipidated HDL |
|
 | | New Approaches for Reduction of TG rich Lipoproteins |
|  | | Apolipoprotein C-III Key Regulator of Serum Triglyceride Levels |
|
 | | Dose-dependent Reduction in Hepatic ApoC-III mRNA Levels |
|  | | Changes in Major Lipid Classes Over 12 Weeks in HTG Rhesus Plasma |
|
 | | New Approaches for Reduction of Inflammation |
|  | | The Balance of IL-1 and IL-1Ra |
|
 | | Canakinumab |
|  | | Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) |
|
 | | Conclusion |
|
Deel deze pagina met collega's en vrienden: